Effects of intracisternal dexmedetomidine on cerebral neuronal cells in rat: a preliminary study.
OBJECTIVE
The aim was to investigate whether dexmedetomidine had a toxic effect on     cerebral neurons when it was administered centrally into the cerebrospinal fluid     by the intracisternal route.


METHODS
Eighteen rats were     anesthetized and the right femoral artery was cannulated. Mean arterial     pressures, heart rates, arterial carbon dioxide tension, arterial oxygen     tension, and blood pH were recorded. When the free cerebrospinal fluid flow was     seen, 0.1 ml normal saline (Group SIC, n=6) or 9 μg/kg diluted     dexmedetomidine in 0.1 ml volume (Group DIC, n=6) was administered into the     cisterna magna of rats. After 24 hours, the whole body blood was collected for     measurement of plasma lipid peroxidation (LPO) levels. The hippocampal     formations used for histopathological examination and measurement of tissue LPO     levels.


RESULTS
There was a statistically significant difference between the     DIC/SIC groups and DIC/CONTROL groups regarding the brain LPO levels (p=0.002, p     < 0.001, respectively). Plasma LPO levels were statistically different     between the CONTROL/DIC groups, CONTROL/SIC groups, DIC/ SIC groups (p=0.002,     p=0.047, p=0.025, respectively), The picnotic neuron counts were different     between the CONTROL/SIC groups, CONTROL/ DIC groups, DIC/SIC groups (p <     0.001, p=0.001, p=0.024, respectively).


CONCLUSIONS
In conclusion,     dexmedetomidine had a toxic effect on cerebral neurons when it was administered     centrally into the cerebrospinal fluid by the intracisternal route.
Kirikkale University, Faculty of Medicine, Department of Anesthesiology and Reanimation, Kirikkale, Turkey. arzuhct@hotmail.com
Emine Arzu
EA
Kose
Bulent
B
Bakar
Omur
O
Kasimcan
Pergin
P
Atilla
Kamer
K
Kilinc
Sevda
S
Muftuoglu
Alpaslan
A
Apan
D058647:Adrenergic alpha-2 Receptor Agonists / Q000633:toxicity*; D000818:Animals; D002946:Cisterna Magna / Q000187:drug effects* / Q000473:pathology; D020927:Dexmedetomidine / Q000633:toxicity*; D006624:Hippocampus / Q000187:drug effects* / Q000473:pathology; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000473:pathology; D010865:Pilot Projects; D051381:Rats; D017208:Rats, Wistar
D058647:Adrenergic alpha-2 Receptor Agonists; D020927:Dexmedetomidine